Back to News
Apr 21, 2026 4:00 PM

Europe Clears First Flu/COVID Combo Shot From Moderna

Moderna Inc. (NASDAQ:MRNA) shares are up on Tuesday as the company received marketing authorization for its mCOMBRIAX vaccine, the world’s first flu plus COVID-19 combination vaccine.

Moderna Gains EU Nod For Combination Flu-COVID Vaccine

The European Commission approved mCOMBRIAX, which aims to simplify immunization for adults aged 50 and older by combining protection against influenza and COVID-19.

The approval marks a significant advancement for Moderna, as mCOMBRIAX is its fourth authorized product.

Phase 3 Data Supports Approval Across Two Age Cohorts

The approval is based on data from Phase 3 trial of mRNA-1083 in two independent age cohorts of approximately 4,000 adults each.

All primary endpoints demonstrating the non-inferiority of immune responses were ...